Underusing Migraine Medication May Be as Harmful as Overusing It

Taking migraine medication too late, in insufficient doses, or not starting preventive treatment early enough may contribute to migraine progression and chronification.

Rattanawong, Wanakorn et al.·Cephalalgia : an international journal of headache·2024·Moderate EvidenceReview
RPEP-09126ReviewModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Review focused on migraine patients at risk for disease progression due to medication underuse
Participants
Review focused on migraine patients at risk for disease progression due to medication underuse

What This Study Found

The review identifies four forms of medication underuse in migraine:

1. Taking inappropriate medications for the pain level and disability

2. Taking medication too late (more than 60 minutes after onset, or after allodynia develops)

3. Discontinuing treatment due to side effects or perceived lack of effect

4. Poor adherence to preventive medications

For acute treatment, the key problem is failing to halt the progression from peripheral nerve activation to central sensitization. Once central sensitization occurs (marked by allodynia, where normal touch becomes painful), acute medications are much less effective.

For preventive treatment, inadequate efficacy and side effects of conventional drugs lead to high discontinuation rates. Anti-CGRP medications partially address this by offering better tolerability and targeting the underlying CGRP pathway. The review suggests starting anti-CGRP treatment during low-frequency episodic migraine rather than waiting until attacks become frequent or chronic.

Key Numbers

  • Acute medication should be taken within 60 minutes of migraine onset
  • Central sensitization (allodynia) marks the point where acute treatment effectiveness drops
  • Anti-CGRP treatment may be more beneficial when started during low-frequency episodic migraine
  • Conventional preventive drugs have high discontinuation rates due to side effects

How They Did This

Comprehensive narrative review of published evidence on medication underuse in migraine, covering both acute and preventive treatments. Examines the pathophysiology of migraine progression from peripheral to central sensitization.

Why This Research Matters

The migraine field has focused heavily on medication overuse headache. This review highlights the opposite problem: not treating enough. If undertreated episodic migraine progresses to chronic migraine, patients face far worse outcomes and quality of life. The recommendation to start CGRP-targeting preventives earlier challenges current stepwise treatment guidelines.

The Bigger Picture

The migraine field has focused heavily on medication overuse. This review highlights an equally important problem — undertreated episodic migraine that progresses to chronic migraine, affecting patient quality of life and healthcare costs.

What This Study Doesn't Tell Us

This is a narrative review advocating a position. The evidence for early CGRP treatment preventing chronification is still limited. The concept of medication underuse is not well-defined in clinical guidelines. Some of the pathophysiology described is based on animal models. The review does not address cost-effectiveness of early CGRP treatment or practical barriers to access.

Questions This Raises

  • ?Could early CGRP antibody treatment prevent chronic migraine development?
  • ?How can clinicians identify undertreated migraine patients?

Trust & Context

Key Stat:
Within 60 minutes Acute migraine medication should be taken within 60 minutes of onset; delaying past this window significantly reduces effectiveness
Evidence Grade:
Rated moderate: evidence-based narrative review presenting a clinical position on underuse, supported by published data.
Study Age:
Published in 2024. Challenges the traditional focus on medication overuse by highlighting the equally important problem of underuse.
Original Title:
Medication "underuse" headache.
Published In:
Cephalalgia : an international journal of headache, 44(4), 3331024241245658 (2024)
Database ID:
RPEP-09126

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Can undertreating migraines make them worse?

Yes — taking medication too late, using the wrong type, or not starting prevention when needed may allow episodic migraines to progress to chronic migraine.

When should you take migraine medication?

Within 60 minutes of onset. After central sensitization (allodynia) develops, acute treatments become much less effective.

Read More on RethinkPeptides

Cite This Study

RPEP-09126·https://rethinkpeptides.com/research/RPEP-09126

APA

Rattanawong, Wanakorn; Rapoport, Alan; Srikiatkhachorn, Anan. (2024). Medication "underuse" headache.. Cephalalgia : an international journal of headache, 44(4), 3331024241245658. https://doi.org/10.1177/03331024241245658

MLA

Rattanawong, Wanakorn, et al. "Medication "underuse" headache.." Cephalalgia : an international journal of headache, 2024. https://doi.org/10.1177/03331024241245658

RethinkPeptides

RethinkPeptides Research Database. "Medication "underuse" headache." RPEP-09126. Retrieved from https://rethinkpeptides.com/research/rattanawong-2024-medication-underuse-headache

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.